Regulation of necrotic cell death by protein kinase A and cylindromatosis

蛋白激酶 A 和圆柱瘤病对坏死细胞死亡的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): Programmed necrosis is a morphologically and molecularly distinct form of cell death from apoptosis. Cell death by necrosis releases endogenous adjuvants or "danger signals" into the tissue milieu, which can trigger inflammation and stimulate immune responses. A role for programmed necrosis in anti-viral immunity is supported by recent discoveries of viral inhibitors that block this pathway of cell death. Mechanistically, programmed necrosis requires the serine/threonine protein kinas RIP1 and is optimally induced when caspases are inhibited. These results highlight a possible role for programmed necrosis in host defense against infectious agents. In order to further understand the molecular mechanism that regulates programmed necrosis, we screened by small interference RNA (siRNA) kinases and cancer-related genes that may participate in this non-apoptotic cell death pathway. We recently described the critical role of another RIP family member identified from the screen, RIP3, in TNF-induced and virus-induced programmed necrosis. In addition to RIP3, protein kinase A (PKA) catalytic subunit b and the tumor suppressor cylindromatosis (CYLD) were also identified from the RNAi screen as crucial for programmed necrosis. In this application, we will examine the molecular mechanisms by which PKA-C2 and CYLD regulates RIP1/RIP3-dependent programmed necrosis. We will examine their recruitment to the pro-necrotic signaling complex and how they might regulate the formation of the pro-necrotic signaling complex. We will determine whether deubiquitinase activity of CYLD is required for its function and explore the possible substrates for CYLD during programmed necrosis. Finally, we will test the physiological relevance of PKA-C2 and CYLD in virus infections using in vitro vaccinia virus infection as a model. PUBLIC HEALTH RELEVANCE: Cell death by necrosis causes inflammation and can greatly impact the quality of an immune response. However, the signals that regulate this process are poorly understood. We have recently identified two molecules, PKA-C2 and CYLD, to be essential for necrotic cell death. In this proposal, we will elucidate the mechanisms by which these two molecules control cell death by necrosis. Furthermore, we will evaluate how these two molecules may affect the cell death response during virus infections. These studies will allow us to better understand the signals that control cell death and inflammation. Eventually, the knowledge gained from these studies will aid the development of strategies to control inflammatory diseases caused by cell injury.
描述(由申请方提供):程序性坏死是一种形态学和分子学上与细胞凋亡不同的细胞死亡形式。坏死导致的细胞死亡向组织环境释放内源性佐剂或“危险信号”,这可引发炎症并刺激免疫反应。最近发现的阻断这种细胞死亡途径的病毒抑制剂支持了程序性坏死在抗病毒免疫中的作用。从机制上讲,程序性坏死需要丝氨酸/苏氨酸蛋白激酶RIP 1,并且当半胱天冬酶被抑制时最佳诱导。这些结果突出了程序性坏死在宿主防御感染因子中的可能作用。为了进一步了解调节程序性坏死的分子机制,我们通过小干扰RNA(siRNA)激酶和癌症相关基因筛选可能参与这种非凋亡细胞死亡途径的基因。我们最近描述了另一个RIP家族成员的关键作用,从屏幕上确定,RIP 3,在TNF诱导和病毒诱导的程序性坏死。除了RIP 3之外,蛋白激酶A(PKA)催化亚基B和肿瘤抑制因子圆柱瘤病(CYLD)也从RNAi筛选中被鉴定为对程序性坏死至关重要。在本申请中,我们将研究PKA-C2和CYLD调节RIP 1/RIP 3依赖性程序性坏死的分子机制。我们将研究它们对促坏死信号复合物的募集以及它们如何调节促坏死信号复合物的形成。我们将确定CYLD的去泛素化酶活性是否是其功能所必需的,并探索程序性坏死过程中CYLD的可能底物。最后,我们将使用体外牛痘病毒感染作为模型来测试PKA-C2和CYLD在病毒感染中的生理相关性。 公共卫生相关性:坏死引起的细胞死亡会导致炎症,并会极大地影响免疫反应的质量。然而,调控这一过程的信号却知之甚少。我们最近已经确定了两种分子,PKA-C2和CYLD,是坏死细胞死亡所必需的。在这个提议中,我们将阐明这两种分子通过坏死控制细胞死亡的机制。此外,我们将评估这两种分子如何影响病毒感染期间的细胞死亡反应。这些研究将使我们更好地了解控制细胞死亡和炎症的信号。最终,从这些研究中获得的知识将有助于制定控制细胞损伤引起的炎症性疾病的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FRANCIS Kaming CHAN其他文献

FRANCIS Kaming CHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FRANCIS Kaming CHAN', 18)}}的其他基金

2020 Cell Death Gordon Research Conference & Gordon Research Seminar
2020细胞死亡戈登研究会议
  • 批准号:
    9890344
  • 财政年份:
    2021
  • 资助金额:
    $ 20.54万
  • 项目类别:
Viral inhibition of cell death in host immune responses
病毒抑制宿主免疫反应中的细胞死亡
  • 批准号:
    10199958
  • 财政年份:
    2020
  • 资助金额:
    $ 20.54万
  • 项目类别:
Necroptosis signaling adaptors in inflammatory diseases
炎症性疾病中的坏死性凋亡信号适配器
  • 批准号:
    9247125
  • 财政年份:
    2016
  • 资助金额:
    $ 20.54万
  • 项目类别:
Necroptosis signaling adaptors in inflammatory diseases
炎症性疾病中的坏死性凋亡信号适配器
  • 批准号:
    9106004
  • 财政年份:
    2016
  • 资助金额:
    $ 20.54万
  • 项目类别:
Programmed necrosis in Immune Responses
免疫反应中的程序性坏死
  • 批准号:
    8049579
  • 财政年份:
    2010
  • 资助金额:
    $ 20.54万
  • 项目类别:
Programmed necrosis in Immune Responses
免疫反应中的程序性坏死
  • 批准号:
    8240975
  • 财政年份:
    2010
  • 资助金额:
    $ 20.54万
  • 项目类别:
Regulation of necrotic cell death by protein kinase A and cylindromatosis
蛋白激酶 A 和圆柱瘤病对坏死细胞死亡的调节
  • 批准号:
    8034218
  • 财政年份:
    2010
  • 资助金额:
    $ 20.54万
  • 项目类别:
Programmed necrosis in Immune Responses
免疫反应中的程序性坏死
  • 批准号:
    8442199
  • 财政年份:
    2010
  • 资助金额:
    $ 20.54万
  • 项目类别:
Programmed necrosis in Immune Responses
免疫反应中的程序性坏死
  • 批准号:
    7889520
  • 财政年份:
    2010
  • 资助金额:
    $ 20.54万
  • 项目类别:
Regulation of TRAIL-induced apoptosis
TRAIL 诱导的细胞凋亡的调节
  • 批准号:
    7669216
  • 财政年份:
    2006
  • 资助金额:
    $ 20.54万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 20.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了